BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $90,776 | -62.0% | 35,880 | 0.0% | 0.00% | – |
| Q2 2023 | $238,961 | -46.6% | 35,880 | +49.5% | 0.00% | – |
| Q1 2023 | $447,840 | -13.1% | 24,000 | 0.0% | 0.00% | – |
| Q4 2022 | $515,520 | +101.4% | 24,000 | +10.6% | 0.00% | – |
| Q3 2022 | $256,000 | -10.5% | 21,700 | 0.0% | 0.00% | – |
| Q2 2022 | $286,000 | -66.9% | 21,700 | -47.5% | 0.00% | – |
| Q1 2022 | $865,000 | -97.2% | 41,368 | -97.3% | 0.00% | -100.0% |
| Q4 2021 | $30,673,000 | -0.9% | 1,508,768 | +47.9% | 0.01% | -8.3% |
| Q3 2021 | $30,965,000 | +13.0% | 1,020,255 | +8.2% | 0.01% | +9.1% |
| Q2 2021 | $27,411,000 | -22.2% | 943,260 | +15.6% | 0.01% | -26.7% |
| Q1 2021 | $35,213,000 | +11.2% | 815,881 | +19.0% | 0.02% | 0.0% |
| Q4 2020 | $31,666,000 | +23.7% | 685,411 | +16.1% | 0.02% | +7.1% |
| Q3 2020 | $25,595,000 | -4.3% | 590,285 | +17.0% | 0.01% | -12.5% |
| Q2 2020 | $26,739,000 | +9623.3% | 504,405 | +4000.9% | 0.02% | – |
| Q1 2020 | $275,000 | – | 12,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |